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ABSTRACT 23 
For the creation of scaffolds in tissue engineering applications, it is essential to control the 24 
physical morphology of fibres and to choose compositions which do not disturb normal 25 
physiological function. Collagen, the most abundant protein in the human body, is a well-26 
established biopolymer used in electrospinning compositions. It shows high in-vivo stability 27 
and is able to maintain a high biomechanical strength over time. In this study, the effects of 28 
collagen type I in polylactic acid-drug electrospun scaffolds for tissue engineering 29 
applications are examined. The samples produced were subsequently characterised using a 30 
range of techniques. Scanning electron microscopy analysis shows that the fibre 31 
morphologies varied across PLA-drug and PLA-collagen-drug samples  ? the addition of 32 
collagen caused a decrease in average fibre diameter by nearly half, and produced 33 
nanofibres. Atomic force microscopy imaging revealed collagen-banding patterns which 34 
show the successful integration of collagen with PLA. Solid-state characterisation suggested 35 
a chemical interaction between PLA and drug compounds, irgasan and levofloxacin, and the 36 
collagen increased the amorphous regions within the samples. Surface energy analysis of 37 
drug powders showed a higher dispersive surface energy of levofloxacin compared with 38 
irgasan, and contact angle goniometry showed an increase in hydrophobicity in PLA-39 
collagen-drug samples. The antibacterial studies showed a high efficacy of resistance against 40 
the growth of both E. coli and S. Aureus, except with PLA-collagen-LEVO which showed a 41 
regrowth of bacteria after 48 h. This can be attributed to the low drug release percentage 42 
incorporated into the nanofibre during the in vitro release study. However, the studies did 43 
show that collagen helped shift both drugs into sustained release behaviour. These ideal 44 
modifications to electrospun scaffolds may prove useful in further research regarding the 45 
acceptance of human tissue by inhibiting the potential for bacterial infection. 46 
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1. INTRODUCTION 51 
Within the field of tissue engineering, there are a number of different applications that can 52 
be explored relating to the combination of synthetic and natural polymers, and integration 53 
with various active pharmaceutical ingredients. For example, surgical wound closure 54 
involves the bringing together of opposing surfaces using glues, staples and/or sutures.  The 55 
re-joined tissues then undergo a primary hyper-proliferative stage, characterised by clot 56 
formation and the recruitment of inflammatory cells (macrophages) into the wound1. 57 
Secretion of local tissue mediators encourages cell migration and begins the process of scar 58 
formation2. Wound contraction, a result of tissue remodelling, increases the tensile strength 59 
of skin across lesions and increases (or decreases) the risk of ruptures. During the healing 60 
stage, the tissue is open to infection itself and as a pathway into deeper tissue structures. 61 
Infection can result in significant complications (e.g. prolonged systemic antibiotic 62 
administration, re-operation for debridement) for the patient in the short and long-term.  In 63 
supporting healing, the purpose of an added matrix task may be to provide tensile strength, 64 
to encourage controlled epithelialisation and new vascular growth and to decrease the 65 
formation of bacterial biofilms. The fabrication of scaffolds for wound repair has become 66 
important, especially the formation of tissue-specific scaffolds3. 67 
For the creation of scaffolds it is essential to mimic the chemical composition, the physical 68 
morphology, and the biological functions of the human body4. Scaffolds can be created 69 
using synthetic polymers (e.g. polycaprolactone) or natural polymers (e.g. chitosan), or a 70 
combination of both  ? the addition of natural polymers can be highly advantageous as these 71 
may avoid the stimulation of chronic inflammation, immunological reactions and toxicity5. 72 
An example of a natural polymer is collagen, which is the most abundant protein in the 73 
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human body, a key element of the extracellular matrix (ECM), and imparts structural 74 
integrity and tensile strength to tissues6. Using collagen in scaffolds has been previously 75 
shown to show a high in vivo stability and is able to maintain a high biomechanical strength 76 
over time7.  77 
One method that is commonly used to fabricate scaffolds for tissue engineering is 78 
electrospinning. The technique utilises electrostatic forces to stretch a dilute polymer 79 
solution as it solidifies8. It is an ideal micro- and nanofibre fabrication technique for tissue 80 
engineering, as the fibres within the resulting scaffold closely mimic the size and structure of 81 
the native extracellular matrix9 and the use of solvent and aqueous based systems are 82 
useful for the integration of biological compounds, such as collagen. Various practices of 83 
electrospinning collagen, including collagen-elastin blends10, collagen-polycaprolactone 84 
scaffolds for vascular tissue engineering11, and fibrinogen fibres which allows native 85 
deposits of collagen during cell growth12 have previously been studied. Despite these 86 
examples of electrospinning involving collagen, there is an apparent gap in the research 87 
concerning the integration of drugs in these electrospun scaffolds. The integration of drugs, 88 
such as antibiotics, with polymer-collagen blends may be critical in the future success of 89 
human tissue accepting the scaffolds; there are many clinical applications for scaffolds that 90 
require controlling growth of bacteria. For example, one of the requirements for controlling 91 
intra-abdominal infection is to maintain satisfactory levels of an antimicrobial drug during 92 
drug administration13. In this regard, the sustained release of drugs is critical to the success 93 
of the device. Sustained release of drugs with electrospun materials have been previously 94 
studied, including polylactic acid with diclofenac sodium (an anti-inflammatory agent)14, 95 
metronidazole-loaded polycaprolactone nanofibres15, and polyvinylidene fluoride with 96 
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enrofloxacin (antibiotic)16. Given the range of success there has been with electrospinning 97 
polymer with drug, and polymer-collagen blends, the next area of research should be to 98 
determine whether we can alter any of the characteristics of scaffolds with the inclusion of 99 
collagen, whether it be mechanical, chemical or drug release changes. 100 
The purpose of this study is to examine the physicochemical properties, bacterial response, 101 
drug loading and bio-functionalisation of electrospun scaffolds that have been prepared 102 
using Type I Collagen with a supporting synthetic polymer. The polymer chosen for this 103 
study is Polylactic-acid (PLA), a biodegradable and biocompatible polymer. It has been 104 
approved by the US Food & Drug Administration for safe clinical use as resorbable sutures17. 105 
PLA has also been used clinically for foot fractures (PLA pins)18, temporary implants19 and 106 
drug delivery carriers20.  In this study, solutions were modified by the addition of type I 107 
collagen. The matrix was loaded and electrospun with two drugs, triclosan (an antibacterial 108 
agent used commonly in soaps, detergents and surgical cleaning agents) or levofloxacin (a 109 
broad-spectrum quinolone antibiotic used commonly in clinical practice to treat 110 
gastrointestinal infections). The electrospun fibres were then characterised through various 111 
methods: the morphology of the electrospun fibres was characterised by scanning electron 112 
microscope (SEM) and Atomic Force Microscope (AFM), solid state characterisation was 113 
performed by x-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC), 114 
surface characterisation of the two drugs was investigated by surface energy analysis (SEA) 115 
and contact angle goniometry (CAG), and drug efficacy (e.g. in vitro release studies, 116 
antibacterial studies and time-of-flight secondary ion mass spectrometry (ToF-SIMS)). The 117 
results from this study should help to build a profile of data in order to aid future work with 118 
regards to tissue engineering research specific to the controlled release of drugs. 119 
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2. MATERIALS & METHODS 120 
2.1 Materials 121 
Polylactic acid (PLA) with a mixed molecular weight was the chosen polymer for this study 122 
and was used as purchased from the suppliers (Sigma-Aldrich, GF45989881), and the 123 
collagen used was type I from calf skin (Sigma-Aldrich, C9791). Irgasan (5-Chloro-2-(2,4-124 
dichlorophenoxy)phenol), Triclosan, >97%, (Sigma-Aldrich, 72779) and levofloxacin ((S)-9-125 
fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-126 
benzoxazine-6-carboxylic acid)  >98%, (Sigma-Aldrich, 28266) were obtained commercially. 127 
The solvents used for the electrospinning were also commercially purchased from Sigma-128 
Aldrich, specifically chloroform (anhydrous, containing amylenes as stabilizers grade, >99%), 129 
N,N-dimethylformamide (DMF, anhydrous grade 99.8%) and 1,1,1,3,3,3-hexafluoro-2-130 
propanol, (GC grade >99%).  131 
2.2 Preparation of PLA Solutions 132 
Investigations of the polymer-drug solutions prepared showed that the optimum w/w 133 
concentration for electrospinning was 8%. This particular concentration was used as 134 
previous experimentation revealed that higher concentrations did not result in suitable fibre 135 
formation (suitable meaning regular fibre diameters and no signs of beading, data not 136 
shown). PLA (8% w/w), and a 9:1 (w/w) ratio of chloroform (CLF) to N,N-dimethylformamide 137 
(DMF). For the formulations containing collagen type I, both polymers were solubilised in 138 
hexafluoropropanol (HFP) with a total polymer (collagen + PLA) concentration of 8%. PLA 139 
was blended with collagen containing 1% collagen (MPLA / [MCollagen + MPLA] x 100)21. Collagen 140 
at a 1% concentration was used as higher concentrations, in the range 2% to 10% w/w, 141 
yielded unstable and inconsistent fibre formations. 142 
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The solutions were mixed through 30 min in the centrifuge, a further 30 min in a sonicator 143 
and a final 1 h with a magnetic stirrer, which resulted in a solution that appeared 144 
homogeneous and composed of a single phase. The solution was left overnight, and a 145 
further 30 min of sonication was applied the following morning in order to confirm the 146 
uniformity of the solution. For the irgasan-loaded solutions, the same method was applied, 147 
at a concentration of 1% irgasan w/w. The concentration of the levofloxacin-loaded 148 
solutions was adjusted to 0.5% w/w to facilitate accurate measurement of the drug release 149 
profile.  All the solutions remained clear after preparation.  This process was based on the 150 
method used by Hall Barrientos et al (2016) for solution preparation22. 151 
2.3 Electrospinning 152 
Various scaffolds were fabricated for each polymeric solution, using an in-house 153 
electrospinning apparatus which consisted of a syringe pump (Harvard Apparatus PHD 2000 154 
infusion, US) and two 30kV high-voltage power supplies (Alpha III series, Brandenburg, UK). 155 
The polymer solution was loaded into a 5 mL glass syringe and fed through tubing with a 156 
metal needle tip attached at the end. The needle was clamped into place, to allow for a 157 
high-voltage supply to run through it  ? this allowed for an electric field to be created 158 
between the needle and the target plate. The syringe was clamped to a pump, which 159 
determined the specific injection flow rate of the polymeric solutions. For each of the three 160 
solutions (e.g. unloaded, irgasan loaded, and levofloxacin loaded), 3 varying flow rates of 161 
0.5, 1 and 1.5 mL h-1 were applied across varying voltages of 2 kV  ? 5 kV (across the needles) 162 
and 10 kV  ? 18 kV22. A 21 gauge needle, at a deposition distance of between 10  ? 12 cm was 163 
used. The process was performed at ambient room temperature (approximately 21°C) with 164 
a relative humidity of between 2  ? 4 % (electrospinning was not performed is the relative 165 
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humidity was greater than 5%). The solution was electrospun onto the target that was 166 
covered with aluminium foil, in order for the final material to be removed and used for 167 
further characterisation. 168 
2.4 Scanning Electron Microscopy 169 
A scanning electron microscope (SEM) was used to determine the morphology and 170 
individual fibre diameter of the electrospun PLA solutions (PLA, PLA-IRG, PLA-LEVO, PLA-171 
Collagen, PLA-Collagen-IRG, and PLA-Collagen-LEVO). A Hitachi TM-1000 SEM was used to 172 
analyse various samples, in which the samples were mounted on an aluminium plate with 173 
conductive tape. Images of fibres were taken at various locations of each electrospun PLA 174 
scaffold in order to determine the overall uniformity of fibres (n=5). Prior to imaging, the 175 
samples were sputter coated with gold for 30 s using a Leica EM ACE200 vacuum coater, 176 
repeated three times in order to increase the conductivity of the samples. The samples were 177 
imaged in secondary electron mode at 5 kV. 178 
2.5 Mathematical analysis of fibre diameters 179 
Statistical comparisons of samples were conducted using SPSS 20.0 software package (SPSS 180 
Inc., Chicago IL, USA). Descriptive statistics, analysis of variance, Scheffé post hoc test and 181 
Kolgomorov-Smirnov test were performed using 50 individual fibre diameters of each 182 
samples obtained from the morphological analysis. 183 
2.6 Atomic Force Microscopy 184 
Further morphological analysis was undertaken through atomic force microscopy (AFM). A 185 
Multimode 8 microscope (Bruker, USA), with Scanasyst-Air probes (Bruker, USA) was used in 186 
Peak Force Quantitative Nano Mechanics (QNM) mode23. The imaging of the fibres was 187 
performed under ambient conditions, with a silicon cantilever probe (Bruker). The tip radius 188 
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of the probe and the spring constant were calculated to be in the regions of 0.964 nm (18° 189 
tip half angle) and 0.3947 N/m, respectively. The scan sizes ranged from 200 nm to 25 µm, 190 
at a scan rate of 0.977 Hz with 512-sample resolution. The Roughness Average (Ra) values 191 
were determined by entering surface scanning data, and digital levelling algorithm values 192 
were determined using Nanoscope Analysis software V1.40 (Bruker USA). AFM images were 193 
collected from two different samples and at random spot surface sampling. 194 
2.7 Differential Scanning Calorimetry (DSC) 195 
Differential scanning calorimetry (DSC) was carried out using a Mettler Toledo DSC822 in 196 
order to examine the thermal properties of the electrospun PLA scaffolds. First, the 197 
scaffolds were cut, weighed and placed in the DSC specific aluminium discs. The disc was 198 
then sealed using a press and subsequently placed in the DSC instrument. The parameters 199 
for DSC analysis were set (parameters are detailed below) via the computer software. The 200 
analysis was then run which took approximately 20 min. The method included heating from 201 
25 °C to 220 °C at 10 ° ƐƚĞƉƐ ? ƵƐŝŶŐ ƐƚĂŶĚĂƌĚ  ? ? ʅů ĂůƵŵŝŶŝƵŵ ĚŝƐĐƐ ? ĂŶĚ ĞĂĐŚ ƐĂŵƉůĞ202 
consisted of 4 mg. 203 
2.8 X-Ray Powder Diffraction (XRPD) 204 
XRPD was performed in a Bruker D2 Phaser machine and measurements were taken under 205 
CuKɲƌĂĚŝĂƚŝŽŶ (ʄ= 1.5406 Å), 40 kV and 30 mA as X-ray source with Kb (Ni) filter. Diffraction 206 
ƉĂƚƚĞƌŶƐǁĞƌĞĐŽůůĞĐƚĞĚǁŝƚŚ ?ɽƌĂŶŐŝŶŐĨƌŽŵ ? ?ƚŽ ? ? ? ? 207 
2.9 Contact Angle Goniometry (CAG) 208 
To monitor changes in wettability of the scaffolds, sessile drop contact angle for distilled 209 
water was measured by contact angle goniometry, using a contact angle goniometer (Kruss 210 
G30, Germany)24. 211 
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2.10 Surface Energy Analysis 212 
The dispersive surface energy of the raw drug samples was determined by inverse gas 213 
chromatography using a SEA ?IGC (Surface Measurement Systems). The samples were 214 
packed into 30 cm (3 mm inside diameter) silanised glass columns, plugged at either end by 215 
silanised glass wool. Various dispersive probes were used; undecane, decane, nonane, 216 
octane, heptane, and hexane were injected at a range of fractional surface coverage in 217 
order to determine the concentration free dispersive surface energy25.  218 
2.11 1H NMR Studies 219 
NMR spectra were recorded on a Varian 600 MHz spectrometer at 298.2 ±0.1 K with 220 
CDCl3:DMF (N,N-dimethylformamide), 95:5, V/V% as solvent, using tetramethylsilane (TMS) 221 
ĂƐƚŚĞĐŚĞŵŝĐĂůƐŚŝĨƚƌĞĨĞƌĞŶĐĞĐŽŵƉŽƵŶĚ ?dŚĞƐĂŵƉůĞǀŽůƵŵĞǁĂƐ ? ? ?ʅ> ? ?,EDZƐƉĞĐƚƌĂ222 
were recorded with the pulse and acquire sequence (number of transients=16, number of 223 
points=16384, acquisition time=851.968 ms, relaxation delay=1.5 s). 224 
2.12 In Vitro Drug Release Studies 225 
The drug releases of the irgasan/levofloxacin loaded PLA-blend scaffolds were measured in 226 
order to determine the release profile for each drug. Buffer solutions consisting of 227 
phosphate buffer solution (PBS, pH 7.4) was mixed with 1% sodium dodecyl sulphate (SDS, a 228 
surfactant was used due to the hydrophobic nature of irgasan). The UV absorbance of both 229 
drugs were measured (irgasan at 280 nm26, and levofloxacin at 293 nm27, respectively) at 230 
various time points (e.g.  15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 24 h and then every day up to 231 
192 h). For every measurement 3 ml of solution was taken from the vial (consisting of total 6 232 
ml PBS) and replaced with fresh 3 ml buffer in order to satisfy the perfect-sink conditions. 233 
The samples were stored in a temperature room of 37 ºC. 234 
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2.13 Antibacterial Studies 235 
The antibacterial efficacy of the drug loaded electrospun scaffolds were tested with 236 
Escherichia coli (E. coli) 8739 and Staphylococcus aureus (S. aureus) 29213, bacterial strains 237 
representative of gram-negative and gram-positive bacteria, respectively.  For this study, a 238 
disc agar diffusion method was used. Luria-Bertani (LB) agar was prepared with the LB 239 
medium consisting of 5 g tryptone, 2.5 g yeast extract, 5 g NaCl and 475 ml of deionized 240 
water. The E. coli and S. aureus cultures were grown overnight in 5 ml of solution, with both 241 
bacteria inoculated from a single colony. 150 µL of the E. coli and S. aureus cultures were 242 
spread onto plates of LB agar. 6 plates received an E. coli inoculum, and the other 6 plates 243 
contained the S. aureus inoculum, before adding small pieces of scaffold onto each plate. 244 
Scaffolds containing no drug and no scaffold presence acted as controls. Each scaffold was 245 
placed in triplicate to ensure accurate results. The plates were left for incubation for 48 h, 246 
and subsequently examined at 24 h and 48 h. Diameters of zones in which there was no 247 
bacterial growth were measured, and these were compared across the various drugs and 248 
bacterial strains.  249 
2.14 Time of Flight Secondary Ion Mass Spectrometry (ToF-SIMS) 250 
The analyses were carried out with a ToF-SIMS V instrument (ION-TOF GmbH, Münster, 251 
Germany) equipped with a Bismuth cluster Liquid Metal Ion Gun (LMIG). To overcome 252 
charge build-up on the isolative samples, a low-energy electron beam (21 eV) flood gun was 253 
employed and the sample surface potential was optimised for each analysis. 254 
Spectrometry mode was applied to acquire reference spectra of Levofloxacin, Irgasan and 255 
PLA. Data was recorded in three replicates for both polarities and each acquisition was 256 
made from different areas of the samples used in this study, ovĞƌĂĨŝĞůĚŽĨǀŝĞǁŽĨ ? ? ?ʅŵп257 
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 ? ? ?ʅŵ ? The 30 kV Bi3+ primary ion beam was optimised to deliver a final primary ion dose 258 
density (PIDD) of 8.0 × 1012 (primary ions/cm2) for each spectrum.  259 
High lateral resolution images of the four drug-loaded samples were collected over a 260 
ƐƵƌĨĂĐĞĂƌĞĂŽĨ ? ?ʅŵп ? ?ʅŵ ?ǁŝƚŚĂƌĞƐŽůƵƚŝŽŶŽĨ ? ? ?ǆ  ? ?ƉŝǆĞůƐ ?ƉŝǆĞůǁŝĚƚŚǁĂƐĐŝƌĐĂ ? ? ?261 
ʅŵ ? ? ŝŶ ƚŚĞ ŶĞŐĂƚŝǀĞ ƐĞĐŽŶĚĂƌǇ ŝŽŶ ƉŽůĂƌŝƚǇ ? ǁŝƚŚ Ă ĨŝŶĂů W/ ĞƋƵĂů ƚŽ  ? ? ? п  ? ?12 primary 262 
ions/cm2. The images were then processed using SurfaceLab 6.7 software (ION-TOF, 263 
Münster, Germany). All the mass spectral information was recorded in the m/z range of 0 - 264 
900 Da. 265 
3. RESULTS 266 
3.1 Intermolecular Interactions 267 
Preliminary 1H NMR study performed in liquid phase suggests the absence of any specific 268 
intermolecular interaction between PLA and LEVO. The 1H NMR spectrum of polylactic 269 
revealed two well-defined peaks centered at 5.10 and 1.52 (ppm) with smaller peaks 270 
residing in the vicinity of the main signal (less than 2% in total peak area based on Lorentz 271 
peak fitting) as depicted in Figure 1. The relatively sharp (2-3 Hz half width) and uniform 272 
quartet and doublet signals of polylactic acid indicate a well-defined conformation 273 
throughout the polymer chain, and albeit the varying chain length the chemical 274 
environment of most monomer units is implied to be highly similar allowing for high 275 
mobility on account of the narrow peaks, i.e. high T2. The peaks at 7.26, 7.94, 2.89, and 2.81 276 
are that of CHCl3, the formyl hydrogen of DMF, and the two methyl peaks of DMF, 277 
respectively. The 1H NMR spectrum of polylactic acid doped with 0.1% levofloxacin showed 278 
no difference in the NMR parameters of the polymer; the peaks of levofloxacin were 279 
detected at the expected chemical shift ranges, however these signals appeared with too 280 
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low SNR to be useful for further measurements. It can only be inferred from the NMR 281 
measurements that a possible presence of intermolecular interaction between polylactic 282 
acid and levofloxacin does not bring about detectable changes in the 1H NMR spectra. 283 
3.2 Fibre Morphology 284 
A one-way between-groups analysis of variance (ANOVA) indicated that there are significant 285 
differences (p<0.001) between the investigated formulations. Applying Scheffé post-hoc 286 
comparison, significant differences were confirmed between samples except for PLA 287 
compared with PLA-IRG and PLA-Collagen compared with PLA-Collagen-IRG. The latter was 288 
also corroborated by the overlap between the obtained confidence intervals; whilst in case 289 
of the other samples the confidence intervals are separated from each other. Except for 290 
PLA-Collagen-LEVO, 99.7 % of the measured fibre diameters fall between the range of mean 291 
± 3 SD, and similarities of the mean and median values suggest that these samples are 292 
normally distributed (Figure 2). 293 
Fibre diameter histograms were assayed using Kolgomorov-Smirnov test (p<0.01) of equality 294 
of distributions (Table 2), which indicated that there is no significant difference, when PLA 295 
compared with PLA-IRG; and PLA-Collagen compared with PLA-Collagen-IRG. On the other 296 
hand, distributions of PLA/PLA-IRG; PLA-Collagen/PLA-Collagen-IRG; PLA-LEVO; PLA-297 
Collagen-LEVO were significantly different when compared with each other. It must be 298 
noted that PLA-Collagen-LEVO exhibited the highest coefficient of variation (72.7 %), whilst 299 
PLA-LEVO had the lowest value (17.2 %) (Table 1). 300 
The SEM images (Figure 3) demonstrated a range of morphologies across both polymer-drug 301 
and polymer-collagen-drug electrospun scaffolds. The PLA-drug scaffolds (Figure 3a  ? 3c) 302 
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showed consistent fibre diameter and the addition of IRG and LEVO caused very slight 303 
beading within the fibres.  304 
The AFM images (Figure 4) show the morphology of the fibres at a greater detail and 305 
resolution. PLA-drug scaffolds (Figure 4a  ? 4b) show a slight variation of morphology across 306 
their surfaces; PLA fibres have a relatively smooth surface with what appears to be beading 307 
(possible solvent residue) on the surface, PLA-IRG fibres generally showed smooth 308 
morphology with no signs of active pharmaceutical ingredient (API) or solvent residue on 309 
the surface, whereas the PLA-LEVO fibres showed a rougher morphology which may have 310 
resulted from crystals of the drug at the surface  ? this observation was supported by the 311 
release profile (see: Results, Drug Efficacy). The surface morphology for the PLA-collagen-312 
drug scaffolds (Figure 4d  ? 4Ĩ ?ƐŚŽǁĞĚƚŚĞƉƌĞƐĞŶĐĞŽĨĐŽůůĂŐĞŶ  ?ǁƌĂƉƉŝŶŐ ?ƚŚĞƉŽůǇŵĞƌŝĐ313 
fibres in a helical manner. This morphology was consistent throughout, which may highlight 314 
a helical coating of the collagen through the fabricated scaffolds. There appeared to be no 315 
presence of drug on the surface of these fibres.  316 
3.3 Solid State Characterisation 317 
The graphs in figure 4 indicate the various DSC isotherms for PLA-drug fibres (Figure 5a), and 318 
PLA-Collagen fibres (Figure 5b). For most of the samples, the glass transition temperature 319 
(Tg) is observed around 60°C, the crystallisation temperature (Tc), an exothermic peak, is 320 
observed around 90 - 115°C and the melting point, an endothermic peak, is observed at 321 
~145°C. Overall the Tc for PLA-drug samples is lower than the PLA-collagen-drug samples. In 322 
the case of PLA-IRG (Figure 5a), the Tg appears to be suppressed and a Tc was not measured 323 
at all.   324 
International Journal of Pharmaceutics 
 
17 
Ivan J. Hall Barrientos 
XRPD data shown in figure 5 indicate that PLA fibres are semi-crystalline, indicated by broad 325 
region, followed by a sharp peak at ~17°. It can be observed in Figure 6a that the addition of 326 
IRG causes an increase in the crystallinity of the polymer-drug sample, due to the sharp 327 
polymer peak at ~17°. There are no significant peaks arising within the PLA-IRG graph 328 
related to the IRG intensity. The PLA-collagen-IRG graph indicates that the sample is in an 329 
amorphous state, due to the very broad peak observed from ~5° to ~25°. The graphs 330 
relating to the PLA-LEVO sample (figure 5b) show two significant peaks at ~7° (relating 331 
levofloxacin) and ~17° (relating to PLA). Again, the addition of collagen to these samples 332 
resulted in a broad amorphous peak ranging from ~5° to ~25°. 333 
3.4 Surface Analysis 334 
The dispersive surface energy of powder irgasan was measured at 37.32 mJ/m2, and a BET 335 
specific surface area of 0.0103 m2/g. Levofloxacin had a higher dispersive surface energy of 336 
47.34 mJ/m2 and a BET specific surface area of 0.0481 m2/g. 337 
The contact angle measurements shown in Figure 7 highlight the differences across PLA-338 
drug and PLA-collagen-drug combinations; PLA-LEVO had a lower overall starting and 339 
finishing contact angle (108° ±2.11 to 50° ±2.35 , respectively), compared with the PLA and 340 
PLA-IRG (120° ±1.09 to 80° ±1.22 , respectively). The samples containing collagen had a 341 
greater starting contact angle (130° ±3.42) and final contact angle reading (120° ±4.12). 342 
3.4 Drug Efficacy and Antibacterial Studies 343 
The cumulative drug release profiles are presented in Figure 8; both PLA-IRG and PLA-344 
collagen-IRG samples exhibited sustained release behaviour over 192 h, with a final release 345 
of ~40%. PLA-LEVO exhibited burst release behaviour, releasing ~20% within the first 24 h of 346 
measurement. PLA-collagen-LEVO showed a significantly lower release percentage initially, 347 
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however it appeared to exhibit sustained release behaviour, with a final cumulative release 348 
of 25%.  The total drug content was determined by Concentration × Volume of Medium × 349 
Dilution Factor / 1000 (correction factor). Therefore, % Drug Release = Amount of Drug / 350 
Theoretical Drug Amount × 100.  351 
Antibacterial measurements were taken at 24 h and 48 h (Figure 9, 48 h only). The PLA-drug 352 
samples show a high efficacy to control the growth of both E. coli and S. aureus. In 353 
particular, PLA-LEVO (2.1 cm) had a higher average inhibition zone than PLA-IRG (1.0 cm). 354 
PLA-collagen-IRG resisted both strains of bacteria in a similar manner to the PLA-IRG sample 355 
(average inhibition zone = 1.1 cm). Finally, the PLA-collagen-LEVO sample showed an 356 
average inhibition zone to E. coli of 1.0 cm; however white spores of bacteria were re-357 
forming near the sample. This sample also had a smaller efficacy with inhibiting the growth 358 
of S. aureus, demonstrating an average inhibition zone of 0.4 cm. 359 
3.5 ToF-SIMS 360 
Imaging data showed a difference in the distribution of the APIs in the various strands. The 361 
compounds of interest are identified by unique characteristic ion peaks; PLA at m/z 71 362 
([C3H3O2]-) and m/z 89 ([C3H5O3]-), Levofloxacin at m/z 360 ([C18H19FN3O4]-, [M-H]-) and m/z 363 
316 ([C17H19FN3O2]-), and Irgasan at m/z 287 ([C12H635Cl3O2]- [M-H]-), and isotopes m/z 289 364 
([C12H635Cl237ClO2]-) and m/z 291 ([C12H635Cl37Cl2O2]-). The total ion images and the overlays 365 
of single ion images for the characteristic peaks of PLA, PLA-collagen and the two drugs are 366 
reported in Figure 10. With regards to the PLA-IRG and PLA-LEVO electrospun scaffolds, by 367 
the ion images Irgasan appears to be homogeneously distributed throughout the sample, 368 
whilst the presence of Levofloxacin is concentrated in multiple small regions on the surface 369 
International Journal of Pharmaceutics 
 
19 
Ivan J. Hall Barrientos 
of the fibers. This confirms the data obtained with the AFM analysis and with the release 370 
study  ? (see: Results, Fibre Morphology and Results, Drug Efficacy). 371 
The diagnostic peaks for both the APIs in the PLA-collagen-API samples present normalized 372 
intensities which are 2 to 3 times lower than the corresponding peaks in the PLA-API 373 
samples, making it difficult to comment on their distribution. The reduced signal could be 374 
caused by matrix effects, an artefact of ionization. Here, it is possible that the presence of 375 
collagen in the system suppressed the ionization of the APIs.  Alternatively, it could suggest 376 
a lower concentration of the APIs present on the surface of the PLA-Collagen fibres 377 
compared to the PLA ones, and could be interpreted as a better embedding of the APIs into 378 
the strands. 379 
4. DISCUSSION 380 
4.1 Fibre Morphology 381 
The differences in fibre form between PLA-drug and PLA-collagen-drug samples can be 382 
clearly seen in figures 2 and 3, where the addition of collagen has created smaller diameters 383 
of the fibres. This is due to the nature of collagen fibre formation, which usually form 384 
nanofibres of around 100 nm28. Although, the fibres created in this study are significantly 385 
bigger than other studies (e.g. average collagen fibres diameters = ~400 nm10) this may be 386 
largely due to the blend of PLA and collagen  ? with PLA-drug solutions producing fibres with 387 
a diameter greater than 2 µm. Fibre formation may also be more effective with collagen, 388 
due to the HFP solvent; the low boiling point (58.2 °C) of this solvent allows for a quicker 389 
evaporation during the electrospinning process, which in turn means that the fibres are 390 
being deposited in a dry state. HFP is also a denaturing organic solvent, and therefore the 391 
interaction between solvent and collagen may cause change in the structure of the 392 
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proteins29. When compared to polycaprolactone fibres (as conducted in our previous study) 393 
electrospun in similar conditions, the addition of levofloxacin increased the overall average 394 
fibre diameter (PCL = ~1.83 µm8 PCL-LEVO = ~2.8 µm22). 395 
 It was also observed that the addition of levofloxacin within both PLA and PLA-collagen 396 
blends resulted in a decreased average fibre diameter; this can be linked to the rheological 397 
behaviour of the solutions where levofloxacin increased the viscosity of the solution, which 398 
normally results in a change in fibre size30. There also appears to be evidence of levofloxacin 399 
appearing at the surface of the fibres (figure 4c), however this may be expected for this 400 
particular drug due to the high dispersive surface energy (see Results: Surface Analysis). If 401 
the drug has a high surface energy, this affects the viscosity of the solution, which in turn 402 
alters the surface tension.  403 
The AFM images of the polymer-collagen blends revealed a helical pattern of collagen 404 
around the fibres  ? the fibrils of collagen exhibit a repeating, nano-banding pattern. 405 
Collagen naturally forms a coiled structure, and the underlying alpha chains within the 406 
collagen fibrils could be responsible for the repeating banding pattern observed 31. This may 407 
be useful within a tissue engineering context, given that this repeat banding is thought to 408 
expose a binding site in the native collagen fibril that enhances cell adhesion and migration6. 409 
4.2 Solid State Characterisation 410 
The DSC data was vital in understanding any potential chemical interactions between the 411 
drug and polymer. In figure 5, the PLA-IRG plot, shows that there is no visible exothermic 412 
reaction (Tc) occurring after the initial glass transition phase, and also no indication of the Tm 413 
of the raw IRG drug at around 60 °C  ? this can interpreted as the IRG being fully integrated 414 
within the polymeric structure32. The Tc values recorded were greater in the samples 415 
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containing collagen which may be attributed to dehydration of the collagen33. This may be 416 
indicative of the collagen successfully embedding or interacting with the polymer. A 417 
reduction in the Tg at around 60 °C of the PLA-Collagen-LEVO can be observed, which again 418 
may indicate that there is no presence of free LEVO particle in this sample  ? this is perhaps 419 
why a sustained release behaviour is observed in section 4.4 (drug efficacy).  420 
The data presented by the DSC was effectively confirmed through the XRPD data (figure 6).  421 
The PLA-IRG sample can be seen to remain in a near semi-crystalline form (slight broad 422 
peak, followed by sharp crystalline PLA peak), with no IRG peaks. It can be concluded from 423 
this that the IRG is fully embedded within the polymeric network. Similarly, no IRG peaks 424 
were visible within the PLA-collagen-IRG graph; however, the broad peak does indicate that 425 
the material is in an amorphous form. The PLA-LEVO graph showed a peak, indicating that 426 
the drug is still in crystalline form and is not incorporated uniformly into the polymeric 427 
network. A similar amorphous peak was observed in the PLA-collagen-LEVO peak, which 428 
may indicate a better encapsulation of drug.  429 
4.3 Surface Analysis 430 
Understanding the surface energy of the drug molecules was an important part of this 431 
study, since it has successfully helped to understand the reasons behind particular 432 
behaviour relating to fibre morphology and overall drug encapsulation. The surface energy 433 
analysis of the two drugs indicated a higher dispersive surface energy for levofloxacin 434 
compared with irgasan. Given that IRG and LEVO are both in a crystalline form, and that 435 
polylactic acid is naturally semi-crystalline, there may be an increased possibility of the two 436 
drugs integrating into the polymeric matrix. The two drugs may require a higher energy in 437 
order to disperse properly within the PLA polymeric structure. With irgasan having a lower 438 
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dispersive surface energy and a hydrophobic nature, there may be a reduced energy 439 
requirement for this drug to properly disperse within a solvent solution. If levofloxacin has a 440 
higher dispersive surface energy, then the transfer of energy between LEVO and solvent will 441 
be insufficient to overcome the drug-drug attractions.  Therefore, not all the levofloxacin 442 
molecules in solution will be surrounded by solvent molecules and dispersed fully into 443 
solution34. At equilibrium, hydrophobic molecules preferentially partition into the organic 444 
phase, typically due to a high log P value35 - the log P of levofloxacin is 1.2736 and the log P 445 
of Irgasan is 4.7637.  Based on the positive values on the log P, both drugs are hydrophobic 446 
and Irgasan is more hydrophobic than LEVO. With both drugs and PLA exhibiting a 447 
hydrophobic nature, this suggests that hydrophobic interactions might occur between the 448 
materials. If the hydrophobic interactions are a dominant, this should be more 449 
advantageous in increasing encapsulation efficiency38. 450 
The change in contract angle may reflect the encapsulation of both drugs within the 451 
polymer matrix. It can be clearly seen in figure 7 that the contact angle was lowest for the 452 
PLA-LEVO sample. This can be attributed to the lower hydrophobic nature of levofloxacin, 453 
the high dispersive surface energy and the probability of the drug on the surface of the 454 
fibres (see Results: Fibre Morphology, AFM). With the PLA-collagen-drug samples, the 455 
contact angles are greater, implying that the samples are more hydrophobic. These results 456 
differ from the contact angle measurements in other studies, in particular collagen is found 457 
to have previously increased the hydrophilicity of PLA samples39. It may be the case that the 458 
collagen fibrils have interacted within the polylactic acid based nanofibre. This strong 459 
hydrophobic connection may be linked to the better integration of both irgasan and 460 
levofloxacin.  461 
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4.4 Drug Efficacy 462 
The release profiles of both irgasan and levofloxacin are similar to the results in a previous 463 
study using polycaprolactone22. However, the final cumulative release percentages with 464 
Polylactic acid appear to be lower (Final PCL scaffolds drug release ~50%, PLA scaffolds 465 
~20% to 40%). This may suggest a poorer drug encapsulation with PLA, which may be due to 466 
the fact that PLA is more hydrophilic than PCL40. The hydrophobic interactions between PLA 467 
and IRG may potentially be the cause of the sustained release behaviour in vitro, and the 468 
lower hydrophobic nature of LEVO may be an even further reduction in a strong polymer-469 
drug interaction. As mentioned in the surface analysis section, the higher dispersive surface 470 
energy may cause this weak interaction between PLA and LEVO; AFM images in figure 4 471 
indicating the possible presence of drug at the surface of the fibres. This presence of drug at 472 
the surface would result in a rapid uptake of water, and therefore be the reason behind the 473 
burst release behaviour observed in vitro. The addition of type I collagen to the polymer-474 
drug samples resulted in a difference in release behaviour with LEVO  ? this drug released in 475 
a sustained release time profile, implying that collagen may be directly affecting the release 476 
of the drug. Literature evidence suggests that the hydrophilic, carboxyl functional groups in 477 
the polymer could be interacting with basic functions expressed by the collagen41 which in 478 
turn results in a change in the hydrophobicity of the fibre, which may result in the sustained 479 
release time profile for the levofloxacin with the PLA-collagen sample.  480 
The antibacterial studies were consistent with the drug release profiles, and indicated that 481 
the formulations were effective in inhibiting the growth of E. coli and S. aureus. The larger 482 
zones of inhibition can be seen in the PLA-LEVO sample, which exhibits burst release 483 
behaviour. The smaller inhibition zones for PLA-IRG and PLA-collagen-IRG were indicative of 484 
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the sustained release profiles. The sustained release profile of PLA-collagen-LEVO was also 485 
confirmed, given that there were small areas of bacterial growth  ? this can be attributed to 486 
the low cumulative release percentage at 48 h of the study by which time < 10% of the drug 487 
had been released).  488 
4.5 ToF-SIMS 489 
The visualisation of the distribution of the APIs on the sample surface contributed to gain a 490 
better understanding about the degree of drug encapsulation and in general about the 491 
interactions between the drugs and the fibres. This result concurs with the suggested 492 
explanation with regards to the release behaviour and is consistent with the results from 493 
the other techniques described in this paper. 494 
5. CONCLUSION 495 
It can be seen that the inclusion of type I collagen significantly altered various characteristics 496 
of electrospun polymer-drug scaffolds. The addition of collagen caused an overall decrease 497 
in fibre morphology and average fibre diameter across both sets of drugs, irgasan and 498 
levofloxacin, with nanofibers forming in the PLA-collagen-LEVO samples. AFM images 499 
revealed collagen fibril banding on the surface of the fibres which suggest there is an 500 
interaction between the polymer-drug and collagen. There were also changes in the solid-501 
state characteristics of the samples, given that the DSC results indicate an increase in 502 
amorphousness of the polymer-drug-collagen samples, and this was confirmed through 503 
typically broad peaks in the XRPD results. Most interestingly, the surface energies of the 504 
scaffolds were modified with an increase in the hydrophobicity of the polymer-collagen-505 
drug noted. In particular, the PLA-collagen-LEVO sample showed a high deal of 506 
hydrophobicity, which was unusual given the low hydrophobic nature of LEVO  ? this could 507 
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potentially be attributed to the strong hydrophobic interactions between the PLA and the 508 
hydrophobic banding in collagen fibrils, resulting in better encapsulation of the drug. Finally, 509 
the drug release profiles of the samples appear to change due to the inclusion of collagen, 510 
most significantly demonstrating the shift of the burst release behaviour in PLA-LEVO to 511 
sustained release behaviour within PLA-collagen-LEVO samples. This study is important in 512 
demonstrating that the modification of electrospun scaffolds can be achieved by 513 
incorporating natural polymers, such as collagen  ? and this modification may be useful in 514 
the compatibility and utilisation of tissue engineered structures within the human body.  515 
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Table & Figure Captions 634 
Table 1: Descriptive statistics of the electrospun fibre diameters. 635 
Table 2: Multiple Comparisons.  636 
Figure 1: The 1H NMR spectrum of polylactic acid in CDCl3:DMF, 95:5, V/V%. 637 
Figure 2: Histograms of fibre diameters (a) PLA Unloaded, (b) PLA-IRG, (c) PLA-LEVO, (d) PLA-638 
Collagen (e) PLA-Collagen-IRG, and (f) PLA-Collagen-LEVO. 639 
Figure 3: SEM Images of: (a) PLA Unloaded, (b) PLA-IRG, (c) PLA-LEVO, (d) PLA-Collagen, (e) 640 
PLA-Collagen-IRG, and (f) PLA-Collagen-LEVO. 641 
Figure 4: AFM Images of (a) PLA Unloaded, (b) PLA-IRG, (c) PLA-LEVO, (d) PLA-Collagen (e) 642 
PLA-Collagen-IRG, and (f) PLA-Collagen-LEVO. 643 
Figure 5: DSC Curves of (a) PLA-drug, (b) PLA-Collagen-drugs and (c) raw drugs Irgasan and 644 
Levofloxacin  645 
Figure 6: XRPD Graphs of (a) PLA IRG Blends and (b) PLA LEVO Blends. 646 
Figure 7: CAG Data for PLA-Drug and PLA-Collagen-Drug blends. 647 
Figure 8: Drug release profiles of PLA-drug and PLA-collagen-drug scaffolds. 648 
Figure 9: Images of antibacterial growth after 48 h. (a) PLA-IRG against E. Coli, (b) PLA-IRG 649 
against S. Aureus, (c) PLA-LEVO against E. Coli, (d) PLA-LEVO against S. Aureus, (e) PLA-650 
Collagen-IRG against E. Coli, (f) PLA-Collagen-IRG against S. Aureus, (g) PLA-Collagen-LEVO 651 
against E. Coli, and (h) PLA-Collagen-LEVO against S. Aureus. 652 
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Figure 10: ToF-SIMS data of (a) PLA-IRG, (b) PLA-LEVO, (c) PLA-Collagen-IRG, and (d) PLA-653 
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